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ABSTRACT A critical appraisal and clinical application of Oliveira-Soares R, Silva JE, Correia M, André M. Finasteride 5 mg/day 
treatment of patterned hair loss in normo-androgenetic postmenopausal women. International Journal of Trichology. 2013;5(1):22-
25. doi: 10.4103/0974-7753.114709. 
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Clinical Context 
Linda Jones (pseudonym), a 68-year-old Caucasian woman with a past medical history of hypertension and 
hypercholesterolemia, presented to her primary care physician’s office for her annual well-visit. During the 
interview, Linda expressed feelings of low self-esteem and dissatisfaction of her appearance, particularly in 
relation to her hair. The patient’s hair had been thinning around the crown of the head over the last 5 years, and 
while she tolerated her appearance previously it had now become unbearable to her. On physical exam, decreased 
hair density was apparent around the crown of the head to the extent that scalp was visible. The patient’s hair 
density is consistent with Ludwig stage 1 of female pattern hair loss (FPHL), showing a generalized thinning of 
crown hair starting 1-3cm behind the frontal hairline. Stage 2 and 3 of the Ludwig scale describe a more global 
diffuse thinning and complete loss of hair on the crown, respectively.1 Linda had not been treated clinically for hair 
loss before, however her husband used minoxidil years previously but stopped due to a perceived lack of hair 
growth and thickening. This prompted the discussion of treatment with Minoxidil 2% solution in addition to other 
non-FDA approved treatment modalities. Finasteride, a 5 alpha-reductase inhibitor, currently FDA approved for 
male androgenic alopecia (AGA) at a dose of 1mg/day also fills a controversial role in FPHL treatment at high dose 
of 5mg/day, due to the 1mg/day being found insufficient to produce results.2,3 Linda was skeptical about the 
overall efficacy of the available treatment options for her after seeing her husband’s past dissatisfaction in 
treatment and was concerned that starting a new medication would lead to experiencing potential side effects 
such as irritation or contact dermatitis, and hypertrichosis, without clinical improvement in her hair density.4 
Because of this, Linda wished to defer treatment at the current time until having a discussion with her 
dermatologist for a second opinion about starting a medication for treatment of FPHL. 
Clinical Question 
Is high dose, 5mg/day, finasteride a safe and effective treatment modality for FPHL in postmenopausal women? 
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Research Article 
Oliveira-Soares R, Silva JE, Correia M, André M. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic 
postmenopausal women. International Journal of Trichology. 2013;5(1):22-25. doi: 10.4103/0974-7753.114709 
Related Literature 
PubMed was searched using the term, “Finasteride female androgenic alopecia women,” yielding 85 citations. 8 studies were 
selected for further assessment. Among the relevant articles was a review article of FPHL by Fabbrocini et al., “Female pattern hair 
loss: A clinical, pathophysiologic, and therapeutic review.”4 The review discussed topical and systemic therapeutic options for FPHL 
such as minoxidil, ketoconazole, prostaglandin analogs, and finasteride. The article noted that other entities outside of the more 
historically targeted aspects like genetics and hormones need to be further investigated for their role in the pathogenesis of FPHL 
before more effective therapies can be developed. 
The Won study from 2018, a large retrospective analysis of pre and postmenopausal women from the years of 2012-2016 who were 
prescribed finasteride at a dose of 2.5mg/day.6 The patients’ ages ranged from 30-73 years of age at their initial visit with a mean 
age of 54.1 years as well as a FPHL onset at the age of 17-61 years. Analysis was performed using chart review and images captured 
of the scalp at 3-month intervals and assessed for global change on a three-point scale by two dermatologists (no response, slightly 
improved, significantly improved). Despite the size of the study, it was not selected due to the study design being retrospective via 
chart review, a less reliable method of analysis than a prospective case series like the Oliveria-Soares study. Their design lends itself 
to increased difficulty to control for bias, confounding variables, and being reliant on records kept by others. Additionally, the 
analysis of their results was not stratified by age groups making it difficult to draw conclusions for our 68-year-old patient. 
The Whiting study from 1999 examined the effects of 1mg/day finasteride in 44 postmenopausal women for 12 months and sowed 
no significant change in hair growth.7 This paper was excluded as the appraisal topic due to the subtherapeutic dosage of finasteride 
used in addition to a sample size that was smaller than comparable studies. 
The Trueb study from 2004 evaluated the effects of 2.5 and 5.0mg/day doses of finasteride in 5 postmenopausal women with 
evaluations at 6, 12, and 18 months.8 The study showed significant improvement in hair growth but was excluded as the appraisal 
topic due to the small sample size. 
The Thai and Sinclair study from 2002 followed one participant that used 5mg weekly doses of finasteride after having failed trials of 
spironolactone and cyproterone acetate due to side effects of dizziness and malaise over a 12-month.9 the study showed 
improvement in alopecia but was excluded to the very small sample size. 
The Price study from 2003 evaluated the effects of 1mg/day finasteride over the course of 12 months in 62 postmenopausal women 
and showed no significant improvement in alopecia.2 The study design was high quality, being a double-blind and placebo 
controlled. Additionally, the study was performed in the United States. However, it was excluded because the dosage of finasteride 
used was not the 5mg/day “high dose”. Instead it used a 1mg/day dosage, and only included women aged 41-60 which did not 
include our patient’s age demographic. 
The Yeon study from 201110, used 5mg/day finasteride in 87 normoandrogenic pre and postmenopausal Asian women with FPHL. 
Their results yielded significant improvement in hair density and thickness after 12 months of therapy. However, this study was not 
selected due to the differences in ethnic demographic when compared to our patient as well as its inclusion of both pre and post-
menopausal women. 
Ultimately, a 2013 study by Oliveira-Soares was selected for critical appraisal.5 The study was a prospective case series and was 
selected because it is one of the larger studies available, at 40 participants, and was a prospective analysis. The study only included 
normoandrogenic postmenopausal women, similar to our patient, and utilized a high, 5mg/day, dosage of finasteride. Additionally, 
the study separated results based on age ranges (<60, 60-70, >70) and utilized both subjective and objective analysis through 
measures patient satisfaction and global photograph analysis by dermatologists, respectively. 
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Critical Appraisal 
The study by Oliveria-Soares, et al.5 was a prospective case series that studied normoandrogenic postmenopausal women with FPHL 
who had not received any hair restoration treatment within the last six months. According to the Strength of Recommendation 
Taxonomy (SORT) criteria, this study could be classified as Level 3, as it is a case series.11 Normoandrogenism was considered to be 
normal levels of total testosterone, free testosterone, dehydroepiandrosterone (DHEA), delta-4-androstenedione, and 5α-
dihydrotestosterone (DHT). The treatment consisted of taking oral finasteride at a dose of 5mg/day for 18 months. Efficacy criteria 
included patient satisfaction categorized as impairment, none, moderate, or highly satisfied with the results. Efficacy criteria also 
included photograph assessment by two independent dermatologists with responses categorized as impairment, moderate or no 
improvement, or major. Upon starting treatment patients were medically evaluated and Ludwig score was performed for each 
patient (Ludwig 1 of 15 patients, Ludwig 2 of 16 patients, and Ludwig 3 of 9 patients). Efficacy was evaluated at 6, 12, and 18 months 
as well as a safety evaluation looking at symptomatology, complete blood count, aspartate aminotransferase, alanine transaminase, 
total bilirubin, alkaline phosphatase, blood glucose, urea, creatinine, iron, 17β-hydroxyprogesterone, cortisol, prolactin luteinizing 
hormone (LH), follicle-stimulating hormone, as well as the normoandrogenic criteria stated previously. Additionally, efficacy was 
stratified by age: below 60 (22 patients), 60-70 (13 patients) and over 70 (5 patients). 
After 6 months of finasteride therapy, 22 patients reported significant improvement, 12 moderate improvement, and 6 no 
improvement.5 Using global photo assessment, 16 patients showed significant improvement, 16 showed moderate improvement, 
and 8 showed no improvement. Slight improvement was seen overtime from 6 to 12 to 18 months, but most improvement was seen 
at 6 months. The percentage of patients with major improvement was greater in the below 60 group (12 of 20) than patients 60 to 
70 (4 of 13) and above 70 (0 of 5). Over the course of the study, the only side effects experienced were an elevation in liver enzymes 
for one patient, which normalized without discontinuation of treatment and libido reduction in 4 patients who continued treatment. 
The authors considered these effects tolerable, given the success with treating alopecia.  
A main limitation of this study was that there was no placebo group due to most patients failing previous treatments for FPHL and 
wanting to receive treatment. Additionally, there was no blinding of patient and examiners which could increase the risk of 
performance and detection biases where patients or examiners alter responses knowing they have an expectation of a certain 
result. The voluntary nature of patient recruitment for this study also increased the likelihood of participation bias by potentially 
having more severe or refractory cases of FPHL seek out treatment in this study. An additional limitation of this study was its analysis 
not producing data in reference to number needed to treat (NNT) or number needed to harm (NNH) using a 5mg/day dose of 
finasteride. Another aspect to consider is that the Oliveria-Soares study was conducted in Portugal, not using a US demographic. 
Although the patient’s ancestry is European, this may provide differences physically and culturally with regard to hair characteristics 
views on FPHL. In an effort to eliminate changes in patient satisfaction or dermatological assessment secondary to factors other than 
finasteride treatment all patients were asked to maintain hair color, style, and length throughout the 18 months of therapy. 
Clinical Application 
The Oliveria-Soares et al. study is applicable to our patient because it includes a demographic similar to her in age, 
postmenopausal state, as well as a shared European ancestry.5 This study provides evidence that at a dose of 
5mg/day finasteride is an effective treatment option for postmenopausal FPHL. There was significant improvement 
based on patient satisfaction and dermatological analysis and should be considered in clinical decision making for 
initial or refractory cases. An additional point of consideration, however, is that the group that found the greatest 
benefit with treatment was not our patients age group of 60-69 years old, it was the <60 years of age group. 
Because of this, additional consideration should be made when treating older patients with regard to the 
expectations of treatment results. 
Limited numbers of studies have been done looking at the benefits of finasteride therapy at dosages above 
1mg/day, the recommend dosage for treatment of male AGA. However, studies at levels of 2.5mg/day 3.8 and 
5mg/day 5,10 provided data supporting its efficacy in the treatment of postmenopausal women and its use as a 
clinical treatment modality with minimal, if any, side effects. Based on Linda’s skepticism of minoxidil’s efficacy the 
research suggesting that 5mg/day finasteride is well tolerated and improves FPHL, finasteride is a viable 
therapeutic recommendation for her. 
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Learning points: 
1. Finasteride at a dose of 5mg may be effective in treating FPHL in postmenopausal females, with efficacy 
displayed at doses as low as 2.5mg/day. 
2. Those who seek treatment early and present with alopecia at a younger age are associated with a more 
positive response to treatment. 
3. FPHL is a complex condition that potentially involves elements outside of genetics and hormones which need 
to be examined in greater detail before treatment for FPHL can be optimized. 
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